ArticleDiscover oncology2025
Construction of regulatory T cells specific genes predictive models of prostate cancer patients based on machine learning: a computational analysis and in vitro experiments.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Development and validation of a novel prognostic and for osteosarcoma patients utilizing multiple organelle related genes.Discover oncology · 2026Article
- A GIMAP family signature for prognostic prediction and immune characterization in hepatocellular carcinoma patients.Discover oncology · 2026Article
- Identification and validation of the potential therapeutic value of CASK in osteosarcoma: a computational analysis andFrontiers in oncology · 2026Article
- CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments.Clinical and experimental medicine · 2025Article
- Unveiling the expression and mechanistic role of SYCP2 in cervical lesions.Discover oncology · 2025Article
- SLC39A14 Is a Potential Therapy Target and Prognostic Biomarker for Acute Myeloid Leukemia.Genes · 2025Article
- Construction of a Prognostic Model of Prostate Cancer Based on Immune and Metabolic Genes and Experimental Validation of the Gene AK5.Oncology research · 2025Article
- Machine learning and validation reveal that immune-related genes in systemic lupus erythematosus regulate apoptosis and cycle progression in diffuse large B-cell lymphoma.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiseases are often caused by multiple factors, regulatory T cells specific genes (RTSGs) have been shown to be associated with cancer, however, their role in prostate cancer (PRAD) has not been fully explored.
methodsRTSGs associated with PRAD prognosis were identified using Cox regression analysis and LASSO analysis. Furthermore, a prognostic model was constructed in PRAD based on the 4 RTSGs, and its biological function were analyzed. We evaluated the differences in tumor immune microenvironment based on prognostic signature. Finally, cell experiments confirmed the function of synaptonemal complex protein-2 (SYCP2) in PRAD cells.
resultsThe prognostic value of RTSGs in PRAD patients has been comprehensively analyzed for the first time and identified four RTSGs with prognostic values. A prognosis risk model was constructed based on four RTSGs and its prognostic value was validated on an independent external PRAD dataset. In PRAD patients, this prognostic feature is an independent risk factor and was significantly correlated with clinical feature information of PRAD patients. This feature is also related to the immune microenvironment of PRAD. Cell experiments have confirmed that SYCP2 regulates the apoptosis and cycle progression of PRAD cells significantly. Therefore, SYCP2 may become an important regulatory factor in the progression of PRAD by participating in intracellular functional regulation.
conclusionsThis research provides a fundamental theoretical basis for improving the diagnosis and treatment of PRAD in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.